266 related articles for article (PubMed ID: 25924238)
1. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
[TBL] [Abstract][Full Text] [Related]
2. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
3. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
[TBL] [Abstract][Full Text] [Related]
5. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
[TBL] [Abstract][Full Text] [Related]
6. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
7. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
8. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
10. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
11. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
12. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
13. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Vidriales MB; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Leuk Res; 2009 Dec; 33(12):1706-9. PubMed ID: 19457552
[TBL] [Abstract][Full Text] [Related]
14. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
[TBL] [Abstract][Full Text] [Related]
16. SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
Deng A; Ning Q; Zhou L; Liang Y
Sci Rep; 2016 Jun; 6():27694. PubMed ID: 27291931
[TBL] [Abstract][Full Text] [Related]
17. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
18. Higher Expression of
Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
[No Abstract] [Full Text] [Related]
19. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
